Abstract: Skin is the first barrier preventing microorganism invasion in host. Wounds destroy this defense barrier and, without an appropriate care, may lead to sepsis. Neutrophil activation and immigration plays an important role at the inflammatory stage of wound healing. Neutrophils are known to express proteinase-activated receptors (PARs), which can be activated by serine proteases, also by enzymes involved in wound healing. We previously reported that PAR 2 agonists up-regulate cell adhesion molecule expression and cytokine production by human neutrophils. Here, we demonstrate that PAR 2 agonists (serine proteases as well as synthetic peptides) reduce transendothelial migration of neutrophils and prolong their life in vitro. Synthetic PAR 2 agonist also enhanced protective interferon (IFN)c-induced FccRI expression at neutrophil cell surface. Of note, IFNc is a cytokine, which was used in clinical trials to reactivate human neutrophil functions during sepsis. Moreover, we observed a significant increase of PAR 2 expression on cell surface of neutrophils from septic patients as compared with healthy volunteers. Together, our results indicate that PAR 2 may be involved in the pathophysiology of neutrophil-endothelial interactions during wound healing or later during sepsis in humans, potentially by affecting neutrophil apoptosis, transendothelial migration and Fcc receptor-mediated phagocytosis.
Introduction
Proteinase-activated receptor-2 (PAR 2 ) is the second member of a novel G protein-coupled receptor subfamily with a unique mechanism of receptor activation. Accessible serine proteases cleave the receptor to expose a new, previously cryptic, N-terminal sequence, which serves further as a 'tethered' receptor-activating ligand. To date, four PARs are known [reviewed in Refs. (1, 2) ]. A variety of serine proteinases, including members of the trypsin family, mast cell tryptase, immune cell-derived or microorganismderived enzymes activate PAR 2 (3) (4) (5) (6) (7) (8) . Functional PAR 2 is expressed by cells involved in inflammatory and allergic responses such as mast cells, dendritic cells, eosinophils, macrophages and neutrophils (9) (10) (11) (12) (13) (14) . However, the ability of PAR 2 agonists to act on key neutrophil features such as phagocytosis, apoptosis or transmigration through the endothelium is still uninvestigated. Nonetheless, PAR 2 immunoreactivity can be found on neutrophils during inflammation or delayed wound healing, for example. Thus, PAR 2 may be involved in wound healing (inflammatory stage) or in further progression of inflammation of untreated wounds, which in very serious cases leads to sepsis.
Recent studies indicated an important role for PAR 2 activation in the development of arthritis, acute pancreatitis, airway inflammation, atopic dermatitis, and encephalomyelitis (2, 15, 16) . In some cases, PAR 2 activation led to pro-inflammatory effects (17) (18) (19) , however, under certain conditions to anti-inflammatory protective effects (20, 21) . Changes in main neutrophil functions are known to play a role in bacteria-induced pathologies (wound infection, sepsis or septic shock) as well as in bacteria-induced complications of skin diseases (22, 23) . However, the role of PAR 2 activation in modulation of neutrophil-endothelial interaction and neutrophil apoptosis during such diseases remains elusive.
Interferons (IFNc, IFNa) are known to activate protective functions of human neutrophils and monocytes (phagocytosis, generation of reactive oxygen species, bacterial killing) (24) (25) (26) (27) . IFNc was also used in clinical trials in sepsis for reactivation of monocyte and neutrophil immune functions (28) . However, the ability of PAR 2 agonists to enhance (during combined application) IFNc-induced protective effects at human neutrophils is still unclear.
Previously (29) , we demonstrated that PAR 2 agonists up-regulate the expression of a 4 b 1 and Mac-1 integrins on neutrophil cell surface, and also enhance the production of IL-1b, IL-6, IL-8 by human neutrophils (29) . These integrins and cytokines are known to affect neutrophil transendothelial migration, apoptosis and phagocytic activity [reviewed in Refs. (30, 31) ]. Therefore, we hypothesized that stimulation of human neutrophils with PAR 2 agonists may act on such key neutrophil features in vitro. To explore this, we examined whether PAR 2 agonists affect: (i) human neutrophil apoptosis and (ii) neutrophil transendothelial migration. Further, we investigated the ability of PAR 2 agonist to enhance IFNc-induced protective effect at human neutrophils (expression of Fcc-receptors, which are known to play crucial role in phagocytic activity of these cells). Moreover, we determined whether neutrophils of septic patients show altered PAR 2 cell surface expression as compared with cells from healthy volunteers.
Materials and methods

Reagents
Human recombinant interferon-c (IFNc) was obtained from TebuBio (Offenbach, Germany). Trypsin was purchased from Sigma (Deisenhofen, Germany). Human b-tryptase was expressed in Pichia pastoris and used as described (32) . Human PAR 2 activating peptide with the sequence trans-cinnamoyl-LIGRLO-NH 2 (tcAP) and reverse peptide with sequence trans-cinnamoyl-OLRGIL-NH 2 (tcRP) (Dr. McMaster, University of Calgary, Canada) was used as described previously (29, 33) . Primary antibodies were: unconjugated or fluorescein isothiocyanate (FITC)-conjugated monoclonal mouse anti-human PAR 2 (clone SAM-11) (Santa Cruz Biotechnology, Heidelberg, Germany); monoclonal mouse anti-human CD64 (DakoCytomation, Hamburg, Germany) and secondary antibodies were PE-conjugated goat anti-mouse from Jackson ImmunoResearch (Hamburg, Germany). The FITC-conjugated mouse IgG 1 isotype control antibodies were from PharMingen (Hamburg, Germany). Cell culture reagents were from BioWhittaker (Aachen, Germany), PromoCell (Heidelberg, Germany), Gibco-Life Technologies (Karlsruhe, Germany), Sigma, Beckton-Dickenson (Heidelberg, Germany), Falcon (via Beckton-Dickenson, Heidelberg, Germany), Corning (Schiphool, the Netherlands).
Isolation and culture of human neutrophils
For sepsis studies, the blood from patients who fulfilled the clinical criteria for septic shock, was used (34) . The study of patients with septic shock (n = 19) and healthy volunteers (n = 18, sex and aged matched) was performed with the permission of the Independent Ethics Committee of the University of Ulm (approval No. 82 ⁄ 2002). Exclusion criteria were age <18 years, pregnancy, rapidly progressing underlying disease, HIV ⁄ AIDS, cardiogenic shock as the primary underlying disease, underlying haematological disease, or cytotoxic therapy given within the previous 6 months.
Blood for in vitro experiments with normal human neutrophils was obtained from healthy adult human volunteers in heparinized tubes or in buffy-coats (Deutsches Rotes Kreuz, Muenster, Germany). Polymorphonuclear neutrophils (PMNs) were isolated using lymphocyte separation medium (equivalent of Percoll produced by PAA Laboratories, Cölbe, Germany) followed by hypotonic stress to remove erythrocytes, as described (29, 35) . Neutrophils were cultured in RPMI 1640 medium supplied with: 1% fetal calf serum (FCS), 1% penicillin ⁄ streptomycin, 1% l-Glutamine and 1% non-essential amino acids. After isolation, cells were cultured (37°C, 5%CO 2 ) during 2 h for recovery.
For human neutrophil stimulation, IFNc was used at a concentration of 200 U ⁄ ml. The same IFNc concentration was used in all co-stimulation experiments (together with the PAR 2 agonist). For PAR 2 
Transendothelial migration assay
Transmigration assays were performed as described in details elsewhere (36) . Briefly, 2.2 · 10 5 human microvascular endothelial cells (HMEC)-1 cells were seeded on fibronectin-coated 6.5-mm Transwell filters (Costar, Bodenheim, Germany) with a 5-lm pore size, and were grown at 37°C and 5%CO 2 to confluence. The integrity of the endothelial monolayer was confirmed by Filipin III (Sigma, cat. 4767) staining followed by fluorescent microscopic investigation, and, in parallel by the measurement of transendothelial electric resistance. After 48 h, medium and non-adherent cells were removed. Immediately, 600 ll of assay medium together with chemo-attractant IL-8 (25 ng ⁄ ml) was added to the lower compartment of a twochamber system separated by the Transwell filters. Assay medium consisted of Dulbecco's modified Eagle's medium (PAA Laboratories, Cölbe, Germany) supplemented with 10% FCS, 25 mm HEPES, 2% l-glutamine and 100 U ⁄ ml penicillin ⁄ streptomycin. Always the constant number of neutrophils was taken for assay. Neutrophils (2 · 10 6 cells) in 100-ll assay medium together with stimuli were added to the upper chamber, and cells were subsequently incubated for 2 h at 37°C and 5% CO 2 . Among stimuli were either N-formylmethionyl-leucyl-phenylalanine (fMLP) (a well-known granulocyte activator, used as a positive control, concentation 5 nm) or PAR 2 agonists (mast cell tryptase 10 )7 m; trypsin 10
m). Experiments were routinely carried out in triplicates.
At the end of the assay, the upper chamber was removed and the migrated neutrophils in the lower compartment were collected and quantified in a Casy TT (Schärfe Instruments, Reutlingen, Germany) or Coulter Counter Z2 (Coulter, Krefeld, Germany). Each sample was made in triplicate. Four independent experiments were performed.
Flow cytometric analysis of CD64 and PAR 2 cell surface expression on neutrophils from healthy volunteers and septic patients Briefly, 1 · 10 6 cells from healthy donors were used for each analysis. Cells were washed twice in PBS (1%FCS) and subsequently incubated with primary mouse antihuman CD64 antibody or with anti-human PAR 2 antibody (in both cases 1 lg ⁄ ml) for 30 min on ice. Then, cells were washed and further incubated with PE-conjugated goat anti-mouse (1:50) secondary antibody in PBS (1%FCS) for additional 30 min on ice. Cells, which were incubated with secondary antibody alone served as a negative control. At least 25 000 stained cells were analysed with the FACScalibur and Cell Quest Pro Software (Becton Dickinson, Heidelberg, Germany).
For septic patient studies, whole blood was collected in an EDTA-containing syringe and erythrocytes were lysed using 1 · flow cytometric analysis (FACS) lysing solution (BD PharMingen, San Diego, CA, USA). A total of 10 ll of FITC-labelled anti-human PAR 2 was used for receptor staining at neutrophil surface (20 min at RT). FITClabelled IgG was added for isotype control (negative control) samples. After washing, the leukocytes were reconstituted in a fixing solution (1% paraformaldehyde in PBS). The purity of granulocytes was estimated with anti-CD45 ⁄ anti-CD14 (to exclude monocyte contamination among analysed cells). At least 20 000 stained neutrophils from each donor in both groups were analysed with the FACScalibur and Cell Quest Pro Software (Becton Dickinson).
Annexin-V staining assay
Labelling of apoptotic neutrophils with annexin-V-FITC (37) and counterstaining with propidium iodide for necrotic cells (Annexin V-FITC Apoptosis Detection kit, BD PharMingen) were performed according to manufacturer's instructions. Labelled neutrophils were analysed by flow cytometry using FACScalibur and Cell Quest Pro software (Becton Dickinson).
Statistical analysis
Results are expressed as mean ± SEM. At least three independent experiments have been performed (n > 3). Statistical evaluation was performed by an analysis of variance and Student's t-test. Significance was assigned where P < 0.05.
Results
Proteinase-activated receptor-2 agonist stimulation reduces the transendothelial migration of human neutrophils in vitro Neutrophil-endothelial interactions play a crucial role in the pathophysiology of various skin diseases such as infection, neutrophilc vascular disorders (certain subtypes of vasculitis) or wound healing, for example. We demonstrated previously that PAR 2 agonist treatment affects surface expression of b 1 and b 2 integrins by human neutrophils (29) . Thus, we hypothesized that PAR 2 agonist stimulation of endothelial cells as well as granulocytes may influence migratory ability of the latter. To test this hypothesis, we used an experimental system where both cell types (granulocytes and HMEC-1 endothelial cells) were exposed to PAR 2 agonists during leukocyte migration. We revealed that application of PAR 2 activating serine proteases (trypsin or mast cell tryptase) as well as a synthetic PAR 2 activating peptide (tcAP) leads to significant reduction in the number of neutrophils migrated via endothelial monolayer in comparison with untreated control (Fig. 1) . The magnitude of this effect was very similar for all PAR 2 agonists used in study -about 25 ± 4% of reduction (the application of fMLP, which was used as positive control, led to 60 ± 4% reduction) (Fig. 1 ). Neither treatment with heparin nor PAR 2 reverse peptide (tcRP) resulted in significant changes of neutrophil transendothelial migration (Fig. 1) .
Proteinase-activated receptor-2 agonist stimulation prolongs human neutrophil survival in vitro
Human neutrophils are known to have a relatively short half-life in the circulation [(reviewed in Ref. (30)]. The life span of mature neutrophils may be extended in vitro by incubation with either pro-inflammatory cytokines or with bacterial products (38) . Therefore, we investigated whether treatment of isolated human neutrophils with PAR 2 agonists might extend neutrophil survival in vitro. Indeed, PAR 2 -tcAP stimulation of human neutrophils from healthy donors prolonged cell survival (estimated using population of early apoptotic cells in Annexin V ⁄ propidium-iodide assay) (Fig. 2) . At 6 h after PAR 2 -tcAP application, the amount of early apoptotic neutrophils was 47 ± 4% lower as compared with untreated control cells. However, this trend was still detectable up to 12 h after agonist treatment. Moreover, application of trypsin in a concentration of 10 )7 m also resulted in extended neutrophil survival in vitro.
At 6 h after trypsin stimulation, the amount of early apoptotic cells becomes 21 ± 4% lower as compared with the amount of early apoptotic cells in untreated control samples. Application of trypsin or PAR 2 -tcAP did not change significantly the number of neutrophils in the population of late apoptotic and necrotic cells (data not shown). Stimulation of cultured neutrophils with scrambled PAR 2 -tcRP (negative control) did not affect neutrophil apoptosis in vitro (Fig. 2) .
Effects of IFNc stimulation on PAR 2 expression on the human neutrophil cell surface m; heparin 30 lg ⁄ ml; N-formylmethionyl-leucyl-phenylalanine (fMLP) 5 nm. Four independent experiments were performed, each in triplicates. Results are presented as an average effect of agent application at neutrophil migration (expressed in percents) ±SEM.*P < 0.05, **P < 0.01. m) treated samples. *P < 0.05, ** P < 0.01. Six independent experiments were performed.
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ª 2007 The Authors compared with unstimulated neutrophils. However, the up-regulation of the mean fluorescence intensity (MFI) remains less pronounceable (increased by 33 ± 3% as compared with the level of untreated control) (Fig. 3a) . The situation changes at 12 h after IFNc application (Fig. 3b) . The number of PAR 2 -positive neutrophils remains very similar to the one of untreated control cells (increased by only 18 ± 5% as compared with untreated cells). Nonetheless, the up-regulation of MFI was significant (MFI increases by 98 ± 9% as compared with untreated control) (Fig. 3b) .
Simultaneous application of PAR 2 agonist and interferon c enhances IFNc-induced expression of FccRI (CD64) at neutrophil cell surface
Despite granulocytes from healthy individuals are known to express CD64 at very low level, its display is induced by stimulation of neutrophils with IFNc (31) . Therefore, we investigated whether co-administration of PAR 2 agonist and IFNc might enhance the known IFNc-induced effect at CD64 display on neutrophil cell surface. Indeed, our results suggest that the treatment of human neutrophils with both agents (PAR 2 -tcAP and IFNc) leads to stronger up-regulation of CD64 on neutrophil cell surface than stimulation with IFNc alone (Fig. 4a,b) . The effect of PAR 2 -tcAP and IFNc co-application reaches its maximum at 12 h, but it already becomes significant at 6 h after agonist treatment (Fig. 4a) . At 12 h after agonist application, this effect is characterized by up-regulation of MFI (increased by 41 ± 9% as compared with cells treated with IFNc alone) as well as of the number of positive neutrophils (up-regulated at 90 ± 8% as compared with neutrophils stimulated by IFNc alone) (Fig. 4b) . Of note, co-stimulation of cultured neutrophils with IFNc and the scrambled PAR 2 -tcRP m) . There were no significant changes in CD64 expression after stimulation of neutrophils with either PAR 2 -tcAP or PAR 2 -tcRP (the respective columns at the graph have very small value). Results are presented as an average effect of agent application at the number of CD64-positive neutrophils as compared with untreated control samples (expressed in percents) ±SEM. *P < 0.05, **P < 0.01. Additionally, the difference in average effects between samples stimulated with IFNc alone and co-stimulated with PAR 2 -tcAP and IFNc was analysed. Statistical significance of such difference is marked # P < 0.05, (negative control) did not affect neutrophil CD64 expression as compared with cells stimulated by IFNc alone (Fig. 4a) . Stimulation of human neutrophils either by PAR 2 -tcAP or PAR 2 -tcRP alone also did not affect CD64 cell surface display (Fig. 4a) .
Changes of PAR 2 cell surface display on neutrophils of septic patients Our in vitro data indicate that PAR 2 agonists reduce migration of neutrophils via endothelium and also prolong neutrophil survival, therefore, potentially may promote an increase of neutrophil count in circulation. We also demonstrated that, PAR 2 agonists acting together with IFNc, significantly enhance the effect of latter at CD64 expression on neutrophils, and these results indicate the involvement of PAR 2 activation in phagocytosis. Together, our data suggest that neutrophil PAR 2 could be involved in the pathogenesis of human diseases, where phagocytes are in contact with pathogens in the blood flow. One of such diseases is sepsis. Therefore, we tested whether the level of neutrophil PAR 2 cell surface expression might change in septic patients. Indeed, our data clearly demonstrate an increased (about 82% of up-regulation as compared with healthy volunteers) PAR 2 expression on neutrophils of septic patients (Fig. 5) . Thus, PAR 2 may contribute to the modulation of neutrophil function during human sepsis.
Discussion
In a recent study (29) , we demonstrated the ability of PAR 2 agonists to up-regulate neutrophil cytokine production and motility in 3-D collagen lattices. The main goal of the present study was to further explore the role of PAR 2 on neutrophils with special regard to its capability to modulate neutrophil-endothelial interactions.
Our previous results were predominantly associated with a scenario in which the activation of neutrophil PAR 2 took place in the extracellular matrix, i.e. after cell migration into the extravascular compartment. However, PAR 2 activation on neutrophils in the vascular compartment (before transendothelial migration) cannot be completely excluded, as various natural PAR 2 agonists are released within blood vessel. Among such agonists are endothelial-derived trypsin and factor VII ⁄ Xa, for example (41) (42) (43) . Therefore, in the current study, we focused on the effects of PAR 2 agonists, which are especially important for leukocyte biology in the blood flow. We revealed that PAR 2 agonists down-regulate trans-endothelial migration of human granulocytes in vitro. Moreover, PAR 2 agonists extended neutrophil life span and enhanced the IFNc-induced FccRI (CD64) receptor expression on human neutrophils. The increase in CD64 expression is known to be associated with an enhancement of antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (31, 44) . Consequently, this ability of PAR 2 agonists to enhance IFNc effects strongly indicates that co-activation of PAR 2 and cellular cytokine receptors may affect the progress of acute inflammatory diseases. This idea is linked to our first-time observations that PAR 2 and its proteases may be involved in human diseases in vivo, as demonstrated in septic patients. Our results clearly suggest the involvement of PAR 2 in neutrophil-endothelial interactions by modulating transmigration and apoptosis of human neutrophils.
Transendothelial migration of granulocytes is considered as a key step in immune response to pathogens (45) . However, uncontrolled adhesion to endothelium and recruitment of neutrophils towards the site of inflammation may lead to significant tissue damage and, therefore, to poor prognosis for patient (46, 47) . Thus, only the accurate regulation of granulocyte recruitment in extravascular compartment promotes resolution of inflammation without serious complications. Our in vitro data indicate the potential role of serine proteases and their receptors in the regulation of leukocyte transendothelial migration. Indeed, proteases (trypsin and tryptase) as well as a PAR 2 activating peptide reduced the migration of human neutrophils via endothelial monolayer. Therefore, at an early stage after stimulation, PAR 2 agonists and their receptor may represent an additional system which controls leukocyte recruitment and consequently modulates the intensity of immune response.
Delayed apoptosis of neutrophils migrated in extravascular space can affect the progression of inflammatory responses during infection. This effect is reached via a reduced clearance of neutrophils from the inflamed tissues and therefore via a risk of tissue injury by neutrophil granule contents (48) . On the other hand, extended life of neutrophils in vascular compartment may be beneficial as it secures additional time for the development of adaptive (31) . Therefore, it was of importance to note that PAR 2 agonists (trypsin as well as activating peptide) down-regulate human neutrophil apoptosis. Such an effect of PAR 2 agonists on neutrophil apoptosis together with reduction of transendothelial migration may modulate the amount of human nuetrophils in circulation at early stages after stimulation.
CD64 is a high-affinity Fcc receptor, which is known to be expressed only at a very low level by neutrophils from healthy adults (31, 49) . However, IFNc stimulation or bacterial infections are reported to induce the expression of CD64 on neutrophils (50, 51) . The increase in CD64 display appears to be associated with an enhancement of ADCC and phagocytic activity of neutrophils (31, 44) . As we showed in the current study, PAR 2 -tcAP stimulation alone did not markedly affect CD64 expression on neutrophil cell surface. However, co-application of PAR 2 agonists together with IFNc enhanced the effect of latter. Our data also indicate that IFNc stimulation up-regulates PAR 2 expression on the cell surface of isolated human neutrophils. Therefore, coordinated interactions between IFNc and PAR 2 agonists may represent a mechanism by which IFNc-induced protective effects could be enhanced during bacterial infection.
Sepsis in humans is known to be characterized by a state of immunosuppression associated with shutdown of neutrophil phagocytic activity and some other neutrophil functions (22) . In attempt to reactivate monocyte and neutrophil immune functions, IFNc-intravenous injections were used in clinical trials in sepsis (28) . Considering the ability of PAR 2 agonists to enhance one of IFNc-induced protective effects on human neutrophils in vitro, we investigated whether cell surface expression of neutrophil PAR 2 may be affected during sepsis in human patients. Our study clearly demonstrates the up-regulation of PAR 2 on the neutrophil cell surface in septic patients. In accordance with these findings, the potential role of the combined action of PAR 2 agonist and IFNc during human sepsis represents an innovative field for further investigations.
Neutrophils are the most numerous cells of blood leukocytes and represent the first line of the innate immune defense against infection. Consequently, neutrophils need to be recruited to the site of inflammation very rapidly. During disease state, molecules exist which may support or counteract this capability (52) . Thus, proteases released by endothelial cells, mast cells or neutrophils themselves may be involved in the pathophysiology of cutaneous inflammation and sepsis in humans by affecting neutrophil apoptosis, transendothelial migration and Fcc receptor-mediated phagocytosis. This may be of importance for the regulation of neutrophil activity during infection including septic conditions, inflammation as well as wound healing.
In conclusion, our data demonstrated that PAR 2 agonists are able to enhance the protective IFNc-induced effect on neutrophil function. Moreover, PAR 2 agonists (activating serine proteases or peptides) and their receptor represent an additional system which controls neutrophil transendothelial migration and apoptosis in vitro. Thus, such system may be involved in the changes of neutrophil-endothelial interactions as well as in the enhancement of cytokineinduced effects at neutrophil functions during inflammatory or acute bacteria-induced pathologies in humans.
